Accordingly, a tri-specific antibody that targets the ErbB2, CD3, and CD28, induces the regression of breast cancers through a mechanism involving the CD4-dependent inhibition of the cell cycle progression of the cancer cells [10], moreover highlighting the supportive impact of the CD4+ T cells, in addition to the cytotoxic CD8+ T cells. Here, ERBB2 is linked to cancer.